On August 11, 2026, Cardinal Health reported a nearly 6% year-over-year revenue increase to $63.67 billion for the quarter ending June 30, although this fell short of expectations of $65.03 billion. Adjusted earnings per share (EPS) of $2.60 exceeded the consensus estimate of $2.42, benefiting from a 31-cent per share boost from U.S. government tariff refunds.
Following the earnings report, Cardinal's shares rose over 1%, reaching a record close, although they experienced some profit-taking after hitting an intraday high of $258.30. Analysts remain optimistic about Cardinal's stock due to its strong earnings growth and strategic shift towards high-margin areas like specialty pharmaceuticals and direct-to-patient healthcare delivery.
Despite the revenue miss, the company's ability to generate strong free cash flow and better-than-expected profits indicates robust operational efficiency. The Pharmaceutical and Specialty Solutions segment, which is the largest by sales, saw a 6% revenue increase to $58.85 billion, driven by brand and specialty pharmaceutical sales.
However, regulatory changes affecting drug prices have posed challenges. Cardinal's fee-for-service model allows it to maintain profitability despite these pressures. The Global Medical Products and Distribution segment reported a slight revenue decline to $3.13 billion, impacted by tariff refunds, yet profitability remained strong.
Overall, Cardinal Health's focus on enhancing profitability and diversifying its business model positions it well for future growth, leading analysts to raise their price target from $245 to $265 while maintaining a hold-equivalent rating